Inhaled corticosteroids have no effect on COVID-19 mortality, say researchers

A study conducted by UK researchers has found no evidence to support the hypothesis that regular use of inhaled corticosteroids may have a beneficial effect on mortality outcomes among patients with coronavirus disease 2019 (COVID-19).

The team, which included researchers from the University of Oxford, London School of Hygiene and Tropical Medicine and Imperial College London, found no significant evidence to support that inhaled corticosteroids (ICS) protect against COVID-related death or that these drugs should be used to treat COVID-19 patients outside of clinical trials.

The findings do not support making any adjustments to ICS treatment regimens among patients with COVID-19, say Ben Goldacre and colleagues.

A pre-print version of the paper is available on the server medRxiv*, while the article undergoes peer review.

What led to speculation that ICS may be beneficial?

Severe COVID-19-related outcomes such as hospitalization or death are more likely among older people and those with underlying health conditions. In many cases, such outcomes are due to complications such as acute respiratory distress syndrome and respiratory failure.

However, some early studies of patients with COVID-19 showed that the prevalence of chronic respiratory conditions was unexpectedly low among hospitalized patients.

This led to some scientists speculating that ICS treatments for conditions such as chronic obstructive pulmonary disorder (COPD) and asthma might protect against the development of severe COVID-19.

Examples of proposed protective mechanisms include suppression of SARS-CoV-2 replication and decreased cytokine production. However, ICS use among people with COPD has also been associated with an increased risk for pneumonia and other severe adverse effects.

Evaluating the association between ICS use and COVID-19 mortality

Now, Ben Goldacre and colleagues have evaluated the association between ICS use and COVID-19-related mortality using the OpenSAFELY platform.

This platform links data from primary care electronic health records and deaths registered with the Office for National Statistics for around 40% of the population in England.

The researchers say they developed OpenSAFELY on behalf of NHS England specifically to help address urgent concerns and questions arising from COVID-19 research.

“The greatest strength of this study was the power we had to look at multiple drug treatments as our dataset included medical records from almost 24 million individuals,” writes the team

The researchers followed the association between current ICS use and COVID-19 outcomes (from the 1st March to 6th May 2020) among 148,488 people with COPD and 817,973 people with asthma who had been prescribed respiratory treatments in the four months before 1st March.

The team compared people who were receiving ICS with those on alternative treatments and evaluated the cohorts for the primary outcome of death related to COVID-19.

People with COPD who were using ICS were at a 38% increased risk for death compared with those who were using a long-acting beta-agonist and a long-acting muscarinic antagonist.

Among people with asthma, those on a high-dose of ICS were at a 52% increased risk for death, compared with those using a short-acting beta-agonist (SABA) and people on a low-to-medium dose of ICS were at a 10% increased risk.

No “strong support for a protective effect from ICS”

“Our findings do not provide any strong support for a protective effect from ICS use in these populations, as has been previously hypothesized,” write the researchers.

However, neither do the findings provide evidence that ICS use has a causally harmful effect, they add.

Although the study initially seemed to indicate harmful associations between ICS use and COVID-19 outcomes, Goldacre and colleagues say these associations can be “plausibly explained by unmeasured confounding due to disease severity.”

The team identified a stronger association between ICS and COVID-19 mortality among patients receiving triple versus dual ICS therapy for COPD. However, the ICS content of these two regimens is similar, and any causal effect due to ICS would also be expected to be similar between the groups.

The researchers hypothesized that disease severity rather than ICS use might influence the risk of non-COVID-19-related death and therefore used this as a negative control outcome.

“If any potentially harmful association observed in primary analyses was due to confounding (i.e. people prescribed ICS had more severe underlying respiratory disease than those who did not) we expected to observe a similar association with non-COVID-19 related death in people prescribed ICS.”

Indeed, in the COPD population, the risk of non-COVID-19--related death was 23% higher among individuals who received ICS.

The researchers expect that if they had successfully controlled for between-group differences in disease severity, no association between ICS use and the negative control outcome of non-COVID-19-related mortality would have been observed.

People currently taking ICS should continue taking them as advised

The team says that overall, the study found no evidence of a significant beneficial or harmful effect of regular ICS use on COVID-19-related mortality.

The findings “do not provide evidence to support adjustments in ICS therapy among COVID-19 patients,” write Goldacre and colleagues.

“People currently taking ICS should continue taking them if recommended as part of routine care,” they conclude.

*Important Notice

medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Journal reference:
Sally Robertson

Written by

Sally Robertson

Sally first developed an interest in medical communications when she took on the role of Journal Development Editor for BioMed Central (BMC), after having graduated with a degree in biomedical science from Greenwich University.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Robertson, Sally. (2020, June 22). Inhaled corticosteroids have no effect on COVID-19 mortality, say researchers. News-Medical. Retrieved on May 11, 2021 from

  • MLA

    Robertson, Sally. "Inhaled corticosteroids have no effect on COVID-19 mortality, say researchers". News-Medical. 11 May 2021. <>.

  • Chicago

    Robertson, Sally. "Inhaled corticosteroids have no effect on COVID-19 mortality, say researchers". News-Medical. (accessed May 11, 2021).

  • Harvard

    Robertson, Sally. 2020. Inhaled corticosteroids have no effect on COVID-19 mortality, say researchers. News-Medical, viewed 11 May 2021,


  1. Debbie Barlow Barbera Debbie Barlow Barbera United States says:

    This article is full of lies.  Why would you ever write such an obvious, politically biased article?This website should be shut down.  There are plenty of reputable sites and medical journals that prove that ICS therapy if very effective - however - that does not work for the vaccine dollars at stake and of course, the Presidential Election.  You really are disgusting.

  2. john parks john parks United States says:

    Early Rx with pulmicort is likely a game changer...........

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Delayed second dose strategy with mRNA vaccines may reduce COVID-19 mortality, say researchers